We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Issues Final Guidance on Safety Reviews for NDAs, BLAs
FDA Issues Final Guidance on Safety Reviews for NDAs, BLAs
February 18, 2005
The FDA has announced the availability of final guidance for industry on how to conduct a safety review of a new drug application (NDA) and a biologics license application (BLA).